ANEMIA PREDICTION METHOD IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH COMBINATION ANTIVIRAL THERAPY Russian patent published in 2016 - IPC A61B8/00 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to infectious diseases, and can be used for prediction of anemia that develops in patients with chronic hepatitis C (CHC) as a result of combination antiviral therapy (CAT). Determine the level of viral load (VL, IU/ml) in the blood serum. Concentration of hemoglobin in the blood before CPT (Hb_Baseline, g/dl). Fibrosis level is shown by indirect liver fibroelastography (F, kPa). Calculates a predicted value of the minimum concentration of hemoglobin (Hb_min, g/dl) using the method of multiple linear regression formula. Value of Hb_min<12.0 g/dl indicates a risk of anemia in patients with chronic hepatitis C treated with CBT. Values of Hb_min of 11.9 g/dl to 10.0 g/dl suggest the development of mild anemia. Values of Hb_min of 9.9 g/dl to 8.0 g/dl - moderate anemia. Values of Hb_min <8.0 g/dl - severe anemia.

EFFECT: method allows you to quickly and accurately carry out the forecast for the development of anemia by taking into account the optimum set of indicators.

1 cl, 1 tbl, 2 ex